CPMD CANNAPHARMARX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.8%
TTM net income YoY-25.6%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-114.1%
Operating margin-210.8%
Net margin-779.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-97.3%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets514.2%
Debt / equity—
Current ratio0.05x
Interest coverage-1.70x
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-102.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.36M | $820,137 |
| Cost of revenue | $3.45M | $3.76M |
| Gross profit | -$2.08M | -$2.93M |
| SG&A expense | $489,641 | $145,713 |
| Operating income | -$3.35M | -$3.63M |
| Interest expense | $1.96M | $2.26M |
| Income tax | $0 | $0 |
| Net income | -$11.13M | -$9.91M |
| EBITDA | — | -$3.63M |
| EPS (diluted) | -0.02 | -0.02 |
| Weighted avg. shares (diluted) | 662.50M | 625.28M |
| Balance sheet | ||
| Cash & equivalents | $1,804 | $2,156 |
| Receivables | $164,430 | $1,747 |
| Inventory | $1.12M | $996,250 |
| Current assets | $1.31M | $1.02M |
| PP&E, net | $127,029 | $137,237 |
| Total assets | $7.02M | $10.84M |
| Current liabilities | $31.59M | $25.75M |
| Total liabilities | $37.17M | $30.65M |
| Shareholders' equity | -$30.15M | -$19.81M |
| Shares outstanding | 662.50M | 662.50M |
| Cash flow statement | ||
| Operating cash flow | -$789,102 | -$1.70M |
| Capital expenditure | $5,519 | $0 |
| Free cash flow | -$794,621 | -$1.70M |
| Investing cash flow | $794,269 | $1.70M |
| Financing cash flow | -$5,519 | $0 |
| Depreciation & amortization | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.